«
Identifying a cancer driver is crucial for cancer treatment because it allows the use of targeted therapies, which have less side - effects than conventional chemotherapy drugs, against a particular protein,» said Kurokawa.
361/11: 00 Systematic analysis of mutation distribution in three dimensional protein structures
identifies cancer driver genes.
Not exact matches
When tested on various
cancer patient databases, iCAGES was found to be superior to other computational tools at predicting
cancer drivers from personal genomes and at
identifying beneficial treatment.
«Once
identified, we further tested their role as
cancer drivers, for example by looking at molecules with and without mutations and comparing their structure and function,» he adds.
In 2007, he joined Columbia University as a post-doc, where he developed network - based computational approaches aimed at
identifying key
drivers of initiation and progression of
cancer, as well as mechanisms of therapeutic response and drug resistance.
As the first step in a next generation knowledge system for
cancer, the GDC enables and accelerates efforts to
identify both high - and low - frequency
cancer driver mutations, assists in revealing the genetic determinants of response to therapy, and informs the composition of clinical trial cohorts.
University of Hawai'i
Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at an
Cancer Center researchers have
identified an essential
driver of tumor cell invasion in glioblastoma, the most aggressive form of brain
cancer that can occur at an
cancer that can occur at any age.
The group has used this approach to
identify key
drivers of metastatic
cancer progression, and is leveraging this information to develop novel nanoparticles to block the spread of prostate and other
cancers.
«Just 44 percent of the pediatric
cancer driver mutations in this study matched those
identified in adults,» said senior author Jinghui Zhang, PhD, St. Jude Computational Biology chair.
In particular, I have initiated a team approach that is
identifying and studying recurrent, treatment - refractory
cancers in our clinics using these approaches as a component of evidence - based diagnostic medicine, seeking to better understand the genomic
drivers in these
cancers and to
identify novel treatment approaches that target them, in hopes of obtaining durable responses.
First Major Gene Mutation for Hereditary Prostate
Cancer Found After a 20 - year quest to find a genetic driver for prostate cancer that strikes men at younger ages and runs in families, researchers have identified a rare, inherited mutation linked to a significantly higher risk of the di
Cancer Found After a 20 - year quest to find a genetic
driver for prostate
cancer that strikes men at younger ages and runs in families, researchers have identified a rare, inherited mutation linked to a significantly higher risk of the di
cancer that strikes men at younger ages and runs in families, researchers have
identified a rare, inherited mutation linked to a significantly higher risk of the disease.